Cargando…
A Cost-Effectiveness Analysis of an Adjuvanted Subunit Vaccine for the Prevention of Herpes Zoster and Post-Herpetic Neuralgia
BACKGROUND: Herpes zoster (HZ) develops in up to 50% of unvaccinated individuals who live to 85 years of age, accounting for more than 1 million cases of HZ annually in the United States. A live attenuated vaccine (LAV) for HZ is U.S. FDA approved for persons 50 years or older, though CDC Advisory C...
Autores principales: | Carpenter, Christopher, Aljassem, Annas, Stassinopoulos, Jerry, Pisacreta, Giovanni, Hutton, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631538/ http://dx.doi.org/10.1093/ofid/ofx163.1043 |
Ejemplares similares
-
A Cost-effectiveness Analysis of an Adjuvanted Subunit Vaccine for the Prevention of Herpes Zoster and Post-herpetic Neuralgia
por: Carpenter, Christopher F, et al.
Publicado: (2019) -
Burden of herpes zoster and post-herpetic neuralgia in Sweden
por: Nilsson, Jonas, et al.
Publicado: (2015) -
The impact of herpes zoster and post-herpetic neuralgia on quality-of-life
por: Johnson, Robert W, et al.
Publicado: (2010) -
Herpes zoster in pregnancy leading to keloids and post herpetic neuralgia: A double whammy?
por: Verma, Shyam B., et al.
Publicado: (2013) -
Assessment of the Potential Herpes Zoster and Post Herpetic Neuralgia Case Avoidance with Vaccination in the United States
por: Patterson, Brandon J, et al.
Publicado: (2017)